Clinical Trial

Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency

Study acronym: CECA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The study " Autologous cultured corneal epithelium (CECA) for the treatment of corneal lesions associated with limbal stem cell deficiency" is the first clinical trial of this product manufactured at the LOEX laboratory. The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency. The study is a phase I/phase II study with the goal to evaluate safety and efficacy of the CECA graft for the treatment of human patients suffering from limbal stem cell deficiency. The trial is open to all genders. The inclusion of 5 minors is planned.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2012-12-20; most recent amendment 2025-07-07.
Status change: Active, Not Recruiting → Recruiting 2020-02-06
Status change: Recruiting → Active, Not Recruiting 2019-07-24
Status change: Enrolling by Invitation → Recruiting 2015-03-27
Trial Details
NCT Number NCT01756365
Lead Sponsor CHU de Quebec-Universite Laval
Conditions Limbal Stem Cell Deficiency
Enrollment 54 participants
Start Date 2012-12
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-10